Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
11 - Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
from II - Therapeutic Areas
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
Summary
Scope of Cardiovascular Therapeutics
An estimated 81 million American adults (37.1 percent) have cardiovascular disease (CVD), including coronary artery disease, hypertension, congestive heart failure, and stroke (1). CVD accounts for 36.3 percent of all deaths in the United States (2,400 deaths daily) and is the most common cause of death in developed countries. These chronic diseases usually require lifelong drug treatment, and medications for their treatment or prevention are among the most commonly prescribed drugs worldwide.
Hypertension, congestive heart failure, and other CVDs are often considered as discrete entities, but are, in fact, complex and heterogeneous syndromes mediated by many different pathophysiological mechanisms that eventually result in a similar clinical picture. As a result, clear and reproducible identification of environmental and genetic factors that contribute to these multifactorial diseases is challenging. Adding to the challenges, there is large variability, only a portion of which is genetically determined, among patients in their responses to a drug for a particular disease.
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 115 - 124Publisher: Cambridge University PressPrint publication year: 2012
References
2008
Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspectsClin Pharmacol Ther. 2007 82 606Google Scholar
Pharmacology and physiology of human adrenergic receptor polymorphismsAnnu Rev Pharmacol Toxicol. 2003 43 381Google Scholar
Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicinePharmacol Rev. 2008 60 513Google Scholar
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertensionClin Pharmacol Ther. 2006 80 23Google Scholar
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertensionClin Pharmacol Ther. 2008 84 715Google Scholar
Chronic heart failure: beta-blockers and pharmacogeneticsEur J Clin Pharmacol. 2009 65 3Google Scholar
Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker usersClin Pharmacol Ther. 2009 85 45Google Scholar
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)Am Heart J. 2008 156 397Google Scholar
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarctionJ Hypertens. 2009 27 61Google Scholar
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertensionJAMA. 2008 299 296Google Scholar
Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysisArch Intern Med. 2008 168 1077Google Scholar
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) studyCirculation. 2005 111 3374Google Scholar
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failureJ Am Coll Cardiol. 2004 44 2019Google Scholar
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failureProc Natl Acad Sci USA. 2006 103 11288Google Scholar
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failureN Engl J Med. 2002 347 1135Google Scholar
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survivalBMC Med Genet. 2008 9 93Google Scholar
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failureNat Med. 2008 14 510Google Scholar
SLCO1B1 variants and statin-induced myopathy – a genomewide studyN Engl J Med. 2008 359 789Google Scholar
An association study of 43 SNPs in 16 candidate genes with atorvastatin responsePharmacogenomics J. 2005 5 352Google Scholar
Comprehensive whole genome and candidate gene analysis for response to statin therapy in the TNT cohortCirc Cardiovasc Genet 2009 2 173Google Scholar
Genetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med. 2009 360 363Google Scholar
Pharmacogenetics of aspirin resistance: a comprehensive systematic reviewBr J Clin Pharmacol. 2008 66 222Google Scholar
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest. 2008 133 160SGoogle Scholar
. Estimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med. 2009 360 753
www.warfarindosing.org 2009
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood. 2008 112 1022Google Scholar